Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Authors:
- Frank JacobsenFJFrank Jacobsen
- Billurvan TaskinBTBillurvan Taskin
- Nathaniel MellingNMNathaniel Melling
- Charlotte SauerCSCharlotte Sauer
- Corinna WittmerCWCorinna Wittmer
- Claudia Hube-MaggCHClaudia Hube-Magg
- Martina KluthMKMartina Kluth
- Ronald SimonRSRonald Simon
- Dirk PehrkeDPDirk Pehrke
- Burkhard BeyerBBBurkhard Beyer
- Thomas SteuberTSThomas Steuber
- Imke ThederanITImke Thederan
Open Access
- 26 July 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-11
Abstract
Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair Cross-Complementation Group 1) in prostate cancer progression. To better understand the impact of ERCC1 protein expression in human prostate cancer, a preexisting tissue microarray (TMA) containing more than 12,000 prostate cancer specimens was analyzed by immunohistochemistry and data were compared with tumor phenotype, PSA recurrence and several of the most common genomic alterations (TMPRSS2:ERG fusions: deletions of PTEN, 6q, 5q, 3p). ERCC1 staining was seen in 64.7% of 10,436 interpretable tissues and was considered weak in 37.1%, moderate in 22.6% and strong in 5% of tumors. High-level ERCC1 staining was linked to advanced pT stage, high Gleason grade, positive lymph nodes, high pre-operative serum PSA, and positive surgical margin status (p < 0.0001 each). High ERCC1 expression was strongly associated with an elevated risk of PSA recurrence (p < 0.0001). This was independent of established prognostic features. A subgroup analysis of cancers defined by comparable quantitative Gleason grades revealed that the prognostic impact was mostly driven by low-grade tumors with a Gleason 3 + 3 or 3 + 4 (Gleason 4: ≤5%). High ERCC1 expression was strongly associated with the presence of genomic alterations and expression levels increased with the number of deletions present in the tumor. These latter data suggest a functional relationship of ERCC1 expression with genomic instability. The results of our study demonstrate that expression of ERCC1 - a potential surrogate for genomic instability - is an independent prognostic marker in prostate cancer with particular importance in low-grade tumors.Keywords
This publication has 36 references indexed in Scilit:
- Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy SpecimensEuropean Urology, 2016
- DNA Replication Stress as a Hallmark of CancerAnnual Review of Pathology: Mechanisms of Disease, 2015
- Tissue-based map of the human proteomeScience, 2015
- Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.2014
- Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912Annals of Oncology, 2013
- Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate CancerThe American Journal of Pathology, 2012
- Deficiency of DNA repair nuclease ERCC1‐XPF promotes prostate cancer progression in a tissue recombination modelThe Prostate, 2011
- Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after ResectionAnnals of Surgical Oncology, 2011
- High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancerThe Prostate, 2010
- Original and reviewed nuclear grading according to the Fuhrman systemCancer, 2004